Lantern Pharma (NASDAQ: LTRN), an AI-driven precision oncology company, reported updated Phase 2 HARMONIC trial data demonstrating that LP-300, in combination with carboplatin and pemetrexed, provided a progression-free survival (PFS) benefit that increased with treatment duration in patients with EGFR Exon 21 L858R-mutant non-small cell lung cancer who had progressed following tyrosine kinase inhibitor (TKI) therapy. The emerging data showed a median PFS of 8.9 months among L858R patients treated through up to six cycles, compared with 8.4 months across the overall L858R cohort. The company described the treatment as having an exceptionally clean safety and tolerability profile, supporting a recently FDA-cleared protocol amendment extending LP-300 dosing from six to eight cycles.
This development is significant for the lung cancer treatment landscape, as EGFR-mutant non-small cell lung cancer patients who progress on TKIs have limited options. The HARMONIC trial specifically targets never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. The data suggest that prolonged treatment with LP-300 may offer additional benefit, and the extension to eight cycles could further improve outcomes. The clean safety profile is particularly noteworthy, as it may allow for longer treatment duration without increased toxicity.
Lantern Pharma leverages its proprietary RADR platform, which uses artificial intelligence and machine learning to transform cancer therapy development. The company's pipeline includes LP-184 for solid tumors and pediatric CNS cancers (through its subsidiary Starlight Therapeutics), LP-284 for hematologic malignancies, and LP-300. Additionally, Lantern has launched withZeta.ai, a multi-agentic AI co-scientist platform now commercially available as a subscription-based research platform for the global biomedical and drug development community. This new revenue stream could provide financial stability and accelerate the development of its pipeline.
For business leaders and investors, Lantern Pharma's AI-driven approach and the promising HARMONIC trial data underscore the potential of precision oncology and AI in drug development. The company's ability to identify biomarkers and tailor treatments could lead to more effective therapies with fewer side effects, addressing a significant unmet need in lung cancer. The FDA-cleared protocol amendment also indicates regulatory support for the trial design.
The full press release is available at https://ibn.fm/uaAUc. More information about Lantern Pharma can be found in their newsroom at https://ibn.fm/LTRN.
